-
公开(公告)号：US11180730B2
公开(公告)日：2021-11-23
申请号：US15966290
申请日：2018-04-30
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc.
发明人： Aviv Regev , Ana Carrizosa Anderson , Le Cong , Vijay K. Kuchroo , Meromit Singer , Chao Wang
IPC分类号： C12N5/0783 , A61K35/17 , A61K39/00 , G01N33/50 , A61K45/06 , C12N15/10 , C12Q1/6883
摘要： The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, GATA3 and/or FOXO1 modulation are provided for use as markers, marker signatures and molecular targets. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
-
2.发明申请METHODS FOR MODULATING IMMUNE RESPONSES DURING CHRONIC IMMUNE CONDITIONS BY TARGETING IL-27 INDUCED PATHWAYS 审中-公开通过靶向IL-27诱导途径调节慢性免疫条件下免疫应答的方法公开(公告)号：US20170058026A1
公开(公告)日：2017-03-02
申请号：US15339218
申请日：2016-10-31
IPC分类号： C07K16/24 , C12N15/113
CPC分类号： C07K16/244 , A61K31/713 , A61K38/1709 , A61K38/1793 , A61K38/20 , C07K14/47 , C07K14/54 , C07K14/7155 , C07K16/18 , C07K2317/75 , C07K2317/76 , C12N5/0636 , C12N15/1136 , C12N2310/11 , C12N2310/14 , C12N2310/16 , C12N2501/2303 , C12N2501/2327
摘要： Described herein are novel compositions comprising IL-27 or NFIL-3 modulators (i e , inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating TIM-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases.
摘要翻译： 本文描述了包含IL-27或NFIL-3调节剂（即抑制剂或活化剂）的新型组合物，以及使用这些试剂靶向细胞如功能性耗尽或无应答的免疫细胞以及调节TIM-3活性或表达的方法。 这些组合物，方法和用途可用于治疗慢性免疫病症，例如持续感染，癌症和自身免疫性疾病。
-
3.发明授权公开(公告)号：US11957695B2
公开(公告)日：2024-04-16
申请号：US16396461
申请日：2019-04-26
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc.
IPC分类号： A61K31/573 , A61K35/17 , A61K38/20 , A61K45/06 , A61P35/00
CPC分类号： A61K31/573 , A61K35/17 , A61K38/20 , A61P35/00 , A61K45/06
摘要： The subject matter disclosed herein is generally directed to modulating T cell dysfunctional and effector states by modulating glucocorticoid and IL-27 signaling. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
-
公开(公告)号：US20210130438A1
公开(公告)日：2021-05-06
申请号：US17083235
申请日：2020-10-28
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc.
IPC分类号： C07K14/715 , C12N15/90 , C12N5/0783 , A61K35/17 , C07K16/28 , A61K39/395 , C12Q1/6886 , G01N33/50 , A61P35/00
摘要： The present invention provides novel pan-cancer T cell exhaustion regulators. CXCR6 expressed in CD8+ T cells was specifically identified as regulating anti-tumor immunity. Modulating CXCR6-CXCL16 interaction is useful in modulating anti-tumor immunity. The identified genes may be modulated in T cells for use in adoptive cell transfer. The identified genes may be modulated in vivo.
-
公开(公告)号：US12036240B2
公开(公告)日：2024-07-16
申请号：US16442348
申请日：2019-06-14
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc.
IPC分类号： C12N5/00 , A61K35/17 , C07K14/705 , C07K14/725 , G01N33/50 , C07K16/28
CPC分类号： A61K35/17 , C07K14/7051 , C07K14/70596 , C07K16/2818 , C07K16/2827
摘要： This invention relates generally to compositions and methods for modulating complement component 3 (C3) activity or expression to treat, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells.
-
公开(公告)号：US11897953B2
公开(公告)日：2024-02-13
申请号：US16622636
申请日：2018-06-14
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc.
IPC分类号： A61K35/17 , C07K14/725 , C07K16/28 , C12N5/0783 , A61P35/00
CPC分类号： C07K16/28 , A61K35/17 , A61P35/00 , C07K14/7051 , C12N5/0636
摘要： This invention relates generally to compositions and methods for modulating complement component 3 (C3) activity or expression to treat, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells.
-
公开(公告)号：US20210100774A1
公开(公告)日：2021-04-08
申请号：US17065328
申请日：2020-10-07
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc.
IPC分类号： A61K31/4015 , C12N15/113 , C12N9/10
摘要： The subject matter disclosed herein is generally directed to modulating anti-tumor T cell immunity by modulating steroidogenesis. Steroidogenesis may be modulated with inhibitors of enzymes that synthesize glucocorticoids in a tumor. The inhibitor may target Cyp11a1. The inhibitor may be metyrapone. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
-
8.发明申请公开(公告)号：US20190106679A1
公开(公告)日：2019-04-11
申请号：US15966290
申请日：2018-04-30
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc.
发明人： Aviv Regev , Ana Carrizosa Anderson , Le Cong , Vijay K. Kuchroo , Meromit Singer , Chao Wang
IPC分类号： C12N5/0783 , A61K35/17 , A61K45/06 , C12Q1/6883 , G01N33/50 , C12N15/10
摘要： The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, GATA3 and/or FOXO1 modulation are provided for use as markers, marker signatures and molecular targets. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
-
9.发明申请公开(公告)号：US20190106678A1
公开(公告)日：2019-04-11
申请号：US15966244
申请日：2018-04-30
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc.
发明人： Aviv Regev , Ana Carrizosa Anderson , Le Cong , Vijay K. Kuchroo , Meromit Singer , Chao Wang
IPC分类号： C12N5/0783 , A61K35/17 , A61K45/06 , C12Q1/6883 , G01N33/50 , C12N15/10
摘要： The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, POU2AF1 modulation is provided for use as a marker, marker signature and molecular target. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
-
10.发明申请公开(公告)号：US20220105135A1
公开(公告)日：2022-04-07
申请号：US17494062
申请日：2021-10-05
申请人： The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc. , Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc.
发明人： Meromit Singer , Aviv Regev , Orit Rozenblatt-Rosen , Davide Mangani , Ana Carrizosa Anderson , Vijay K. Kuchroo , Linglin Huang
摘要： The present invention is generally directed to identifying genes and cell types that are correlated with tumor progression in the tumor microenvironment. PENK was identified as a therapeutic target that is positively correlated with tumor time and size. Targeting PENK can enhance anti-tumor immunity. Opioid signaling can be modulated to enhance anti-tumor immunity. The present invention is also generally directed to interacting cells in the tumor microenvironment and using the identified interactions to enhance anti-tumor immunity in cancer. Identified interactions can be modulated using therapeutic agents. Immune cells resistant to suppression can be used for adoptive cell transfer.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.046 秒)
